+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Therapeutic vaccine Market - Segmented by Type, and Geography - Growth, Trends and Forecasts (2018 - 2023)

  • ID: 4470116
  • Report
  • Region: Global
  • 115 pages
  • Mordor Intelligence
until Dec 31st 2019
1 of 4


  • Agenus Inc.
  • Bavarian Nordic
  • Cytos Biotechnology
  • Dendreon Corp
  • Glaxosmithkline
  • Merck Serono
  • MORE
In 2017, the global therapeutic vaccine market was valued at around USD 14.15 billion. North America accounted for the highest market value in 2017, however Middle East & Africa is expected to register the highest CAGR of 12.63% during the forecast period.

Favorable Government Funding for Vaccine Development

The United States nearly spends USD 1.4 billion on vaccine R&D annually, with funds received from various sources. The most recent funding would be Government of Canada’s funding to enhance vaccine research and development which amounts to $1 million. It can be clearly seen that vaccines are of prime importance to the healthcare industry globally as there are many developing regions who are in dire need of vaccines and are a victim of lack of resources. The Global Therapeutic Vaccines market is set to witness great growth opportunities in the recent times. This can be attributed to the growing awareness of communicable diseases and new threats, cost effectiveness of vaccines, development in new research techniques and increasing demand, new target population and emergence of developing markets

Huge Capital Expenditures

With the increasing demand for different types of vaccines to be introduced into the market, there is one drawback to this situation. The vaccine research requires huge capital to be invested and a lot of time to be invested. Vaccines, as with all other regulated products undergo a rigorous review of laboratory and clinical data, to ensure the safety, efficacy, purity, and potency of these products. Vaccines approved for marketing may also be required to undergo additional studies to further evaluate the vaccine and often to address specific questions about the vaccine's safety, effectiveness or possible side effects

North America to Dominate the Market

The Therapeutic vaccine is segmented by type and geography. By geography, the market has been segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.

The United States is the largest market in the North America, which accounts for about 77.97% of the total market volume. Canadian and Mexican markets have high growth potentials and the US market is focused on the invention and development of new vaccines. The demand for better and more efficient vaccines is expected to increase, in order to reduce the shortfall of vaccines during disease outbreaks. The demand for the measles vaccines has increased drastically, due to the worst measles outbreak in North America in 15 years and also for emerging respiratory vaccines.

Key Developments in the Market
  • March 2017, Neon Therapeutics and vedantra Pharmaceutical partnered to develop therapeutic vaccine for cancer.

Reasons to Purchase this Report
  • Market analysis for the Global therapeutic vaccine, with region-specific assessments and competition analysis on a global and regional scale
  • Analyzing various perspectives of the market, with the help of Porter’s five forces analysis
  • The treatment type that is expected to dominate the market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies that are employed by the major market players
  • 3 months analyst support, along with the Market Estimate sheet (in excel)
Customization of the Report

This report can be customized to meet your requirements..
Note: Product cover images may vary from those shown
2 of 4


  • Agenus Inc.
  • Bavarian Nordic
  • Cytos Biotechnology
  • Dendreon Corp
  • Glaxosmithkline
  • Merck Serono
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Favorable Government Funding for Vaccine Development
6.1.2Increasing Investments by the Companies
6.1.3 Technological Advancements
6.1.4 Rising Prevalence of Diseases
6.2 Market Restraints
6.2.1 Huge Capital Expenditures
6.2.2 Stringent Regulatory Framework
6.3 Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 By Type
7.1.1 Auto Immune Disease Vaccines
7.1.2 Neurological Disease Vaccines ACC-001 CAD 106 Parkinson'S Vaccine Alzheimer'S Vaccine
7.1.3Cancer Vaccines Multikine PR1 Peptide Trovax Cyt004-MelQbG10
7.1.4 Infectious Disease Vaccines Hepatitis C Vaccines HIV/AIDS Vaccine Other Infectious Disease Vaccines
7.2 By Geography
7.2.1 North America Canada Mexico
7.2.2 Europe France Germany UK Italy Spain Rest of Europe (RoE)
7.2.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
7.2.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa South America Brazil Argentina Rest of South America

8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches

9. Key Players
9.1 Agenus Inc.
9.2 Bavarian Nordic
9.3 Cytos Biotechnology
9.4 Dendreon Corp
9.5 GlaxoSmithKline
9.6 Pfizer
9.7 Merck Serono
9.8 Novartis

10. Future of the Market
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Agenus Inc.
  • Bavarian Nordic
  • Cytos Biotechnology
  • Dendreon Corp
  • Glaxosmithkline
  • Pfizer
  • Merck Serono
  • Novartis
Note: Product cover images may vary from those shown